» Articles » PMID: 38989936

Metabolic Reprogramming: a New Option for the Treatment of Spinal Cord Injury

Overview
Date 2024 Jul 11
PMID 38989936
Authors
Affiliations
Soon will be listed here.
Abstract

Spinal cord injuries impose a notably economic burden on society, mainly because of the severe after-effects they cause. Despite the ongoing development of various therapies for spinal cord injuries, their effectiveness remains unsatisfactory. However, a deeper understanding of metabolism has opened up a new therapeutic opportunity in the form of metabolic reprogramming. In this review, we explore the metabolic changes that occur during spinal cord injuries, their consequences, and the therapeutic tools available for metabolic reprogramming. Normal spinal cord metabolism is characterized by independent cellular metabolism and intercellular metabolic coupling. However, spinal cord injury results in metabolic disorders that include disturbances in glucose metabolism, lipid metabolism, and mitochondrial dysfunction. These metabolic disturbances lead to corresponding pathological changes, including the failure of axonal regeneration, the accumulation of scarring, and the activation of microglia. To rescue spinal cord injury at the metabolic level, potential metabolic reprogramming approaches have emerged, including replenishing metabolic substrates, reconstituting metabolic couplings, and targeting mitochondrial therapies to alter cell fate. The available evidence suggests that metabolic reprogramming holds great promise as a next-generation approach for the treatment of spinal cord injury. To further advance the metabolic treatment of the spinal cord injury, future efforts should focus on a deeper understanding of neurometabolism, the development of more advanced metabolomics technologies, and the design of highly effective metabolic interventions.

References
1.
Sullivan P, Geiger J, Mattson M, Scheff S . Dietary supplement creatine protects against traumatic brain injury. Ann Neurol. 2000; 48(5):723-9. View

2.
Orihuela R, McPherson C, Harry G . Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2015; 173(4):649-65. PMC: 4742299. DOI: 10.1111/bph.13139. View

3.
Genovese T, Esposito E, Mazzon E, Crisafulli C, Paterniti I, Di Paola R . PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma. Pharmacol Res. 2009; 59(5):338-50. DOI: 10.1016/j.phrs.2009.01.018. View

4.
Yalcin A, Clem B, Imbert-Fernandez Y, Ozcan S, Peker S, ONeal J . 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death Dis. 2014; 5:e1337. PMC: 4123086. DOI: 10.1038/cddis.2014.292. View

5.
Rodriguez-Jimenez F, Jendelova P, Erceg S . The activation of dormant ependymal cells following spinal cord injury. Stem Cell Res Ther. 2023; 14(1):175. PMC: 10324230. DOI: 10.1186/s13287-023-03395-4. View